A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk Blom(University of Cape Town), Evan A. Stein, Lesley Burgess(Stellenbosch University), Kate Tsirtsonis(Amgen (United Kingdom)), Michael A. Bolognese, Tomas Hala(Center for Clinical & Basic Research), Maria Laura Monsalvo(Amgen (United States)), Christie M. Ballantyne(Manpower Demonstration Research Corporation), Michael Lillestol, Robert C. Scott(Amgen (United States)), Jae Bum Kim(Seoul National University), Scott M. Wasserman(Amgen (United States)), Eli M. Roth(Sterling Research Group), R Češka(Charles University), Phillip D. Toth(Midwest Institute for Clinical Research), Michael J. Koren(Jacksonville Center for Clinical Research)
Cited by 712
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k